Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin

被引:49
|
作者
Shlezinger, Mor [1 ,2 ]
Coppenhagen-Glazer, Shunit [2 ]
Gelman, Daniel [2 ]
Beyth, Nurit [1 ]
Hazan, Ronen [2 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Prosthodont, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Dent Sci, Hadassah Sch Dent Med, IL-91120 Jerusalem, Israel
来源
VIRUSES-BASEL | 2019年 / 11卷 / 10期
基金
以色列科学基金会;
关键词
phage therapy; Enterococcus faecalis (VRE); vancomycin; phage EFLK1; phage-antibiotic synergy (PAS); BACTERIOPHAGE; BIOFILM; ANTIBIOTICS; BIOCONTROL; MECHANISMS; EVOLUTION; EFFICACY; ECOLOGY;
D O I
10.3390/v11100954
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Currently, effective options are needed to fight vancomycin-resistant Enterococcus faecalis (VRE). The present study shows that combinations of phage and vancomycin are highly efficient against VRE, despite being resistant to the antibiotic. Vancomycin-phage EFLK1 (anti-E. faecalis phage) synergy was assessed against VRE planktonic and biofilm cultures. The effect of the combined treatment on VRE biofilms was determined by evaluating the viable counts and biomass and then visualized using scanning electron microscopy (SEM). The cell wall peptidoglycan was stained after phage treatment, visualized by confocal microscopy and quantified by fluorescence activated cell sorting (FACS) analysis. The combined treatment was synergistically effective compared to treatment with phage or antibiotic alone, both in planktonic and biofilm cultures. Confocal microscopy and FACS analysis showed that fluorescence intensity of phage-treated bacteria increased eight-fold, suggesting a change in the peptidoglycan of the cell wall. Our results indicate that with combined treatment, VRE strains are not more problematic than sensitive strains and thus give hope in the continuous struggle against the current emergence of multidrug resistant pathogens.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Vancomycin-resistant enterococci: eradication using vancomycin?
    J Van Prehn
    AM Stemerding
    HK Van Saene
    PE Spronk
    Critical Care, 18 (Suppl 1):
  • [2] Vancomycin-Resistant Enterococci
    Rubinstein, Ethan
    Keynan, Yoav
    CRITICAL CARE CLINICS, 2013, 29 (04) : 841 - +
  • [3] Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci
    Baetz, Benjamin
    Boudrioua, Abdelhakim
    Hartke, Axel
    Giraud, Caroline
    ANTIBIOTICS-BASEL, 2021, 10 (09):
  • [4] Vancomycin-resistant enterococci in Austria
    Allerberger, F
    LassFlorl, C
    Dierich, MP
    Hirschl, AM
    Presterl, E
    Haas, G
    Klare, I
    Witte, W
    WIENER KLINISCHE WOCHENSCHRIFT, 1997, 109 (09) : 312 - 320
  • [5] Vancomycin-Resistant Enterococci in a Chinese Hospital
    S. Li
    Z. Zhang
    Z. H. Mi
    Current Microbiology, 2007, 55 : 125 - 127
  • [6] Vancomycin-resistant enterococci in a Chinese hospital
    Li, S.
    Zhang, Z.
    Mi, Z. H.
    CURRENT MICROBIOLOGY, 2007, 55 (02) : 125 - 127
  • [7] Clinical impact of vancomycin-resistant enterococci
    Patel, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 : 13 - 21
  • [8] Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci
    Muehlberg, Eric
    Umstaetter, Florian
    Domhan, Cornelius
    Hertlein, Tobias
    Ohlsen, Knut
    Krause, Andreas
    Kleist, Christian
    Beijer, Barbro
    Zimmermann, Stefan
    Haberkorn, Uwe
    Mier, Walter
    Uhl, Philipp
    PHARMACEUTICALS, 2020, 13 (06)
  • [9] Optimizing therapy for vancomycin-resistant enterococci (VRE)
    Linden, Peter K.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (06) : 632 - 645
  • [10] Vancomycin-resistant enterococci (VRE): a reason to isolate?
    Vehreschild, Maria J. G. T.
    Haverkamp, Miriam
    Biehl, Lena M.
    Lemmen, Sebastian
    Faetkenheuer, Gerd
    INFECTION, 2019, 47 (01) : 7 - 11